And it's being fueled by a strong fundamental tailwind.
April 6, 2026
There aren't any new S&P 500 earnings reactions to cover, so we want to tell you about one of our favorite earnings reactions from this quarter outside of the S&P 500.
LeMaitre Vascular $LMAT is a small-cap medical device company that most investors have never heard of, but it plays a critical role in treating peripheral vascular disease, a condition that affects over 200 million people worldwide.
They design and sell specialized surgical tools, implants, and grafts that vascular surgeons rely on in life-saving procedures.
These aren’t flashy products, but they are essential, highly specialized, and deeply embedded in hospital workflows.
That’s the kind of business that tends to come with pricing power, recurring demand, and long-term growth.
And when you look at the chart, it’s clear the market is starting to recognize exactly that.
After a strong run into late 2024, LMAT spent more than a year going sideways.
At first glance, it looks like nothing happened. But that’s actually where the foundation was built.
That long, rounded stretch is a classic base, a period when supply is absorbed, and ownership transitions to stronger hands.
The stock wasn’t broken… it was preparing for the next leg higher.
Then came the catalyst.
The February earnings report triggered a massive re-rating. LMAT surged more than 24% in a single session, the biggest earnings reaction in its history, and instead of giving it back, the stock held firm.
Since then, price has tightened up just below those prior highs, coiling into a clean consolidation as volatility contracts.
And if this resolves higher, there’s no overhead supply left to slow it down.
But what makes this setup so compelling is that the fundamentals fully support what we’re seeing in the price.
In the most recent quarter, LMAT delivered 16% revenue growth, while operating income jumped 47% and earnings grew nearly 40%.
That’s not just growth, that’s leverage. The business is becoming more profitable as it scales, which is exactly what you want to see at this stage.
They’re also proving they have real pricing power. Management pushed through roughly an 8% price increase across their product portfolio this year, and hospitals largely accepted it without issue.
That’s a strong signal that these products are not easily replaceable.
When your customers aren’t pushing back on price hikes, it usually means you’re selling something they can’t operate without.
At the same time, growth is coming from multiple angles.
Different product lines are contributing, international markets are accelerating, and newer offerings like Artegraft are gaining traction faster than expected.
In fact, management now believes the opportunity for that product is significantly larger than they initially estimated, which is exactly the kind of upside surprise that can drive sustained earnings momentum.
All of this feeds back into how the stock behaves.
That explosive earnings reaction wasn’t a one-off event. It was the market adjusting to a stronger, more durable growth story.
And now, instead of fading, the stock is tightening near highs, a sign that buyers are still in control.
So you’ve got a company with essential products, expanding margins, global growth tailwinds, and a market that’s starting to reward it.
And you’ve got a chart that reflects all of it.
If LMAT breaks out from this coil, we'll have confirmation that the market is continuing to reprice a business executing at a very high level.
They covered where energy goes from here, what's setting up behind it, and the position-sizing framework that separates the traders who make money in commodity cycles from those who don't.
